A calcium-dependent protease as a potential therapeutic target for Wolfram Wolfram syndrome | endoplasmic reticulum | diabetes | neurodegeneration | treatment T he endoplasmic reticulum (ER) takes center stage for protein production, redox regulation, calcium homeostasis, and cell death (1, 2) . It follows that genetic or acquired ER dysfunction can trigger a variety of common diseases, including neurodegenerative diseases, metabolic disorders, and inflammatory bowel disease (3, 4) . Breakdown in ER function is also associated with genetic disorders such as Wolfram syndrome (5) (6) (7) (8) . It is challenging to determine the exact effects of ER dysfunction on the fate of affected cells in common diseases with polygenic and multifactorial etiologies. In contrast, we reasoned that it should be possible to define the role of ER dysfunction in mechanistically homogenous patient populations, especially in rare diseases with a monogenic basis, such as Wolfram syndrome (9) .
Wolfram syndrome (OMIM 222300) is a rare autosomal recessive disorder characterized by juvenile-onset diabetes mellitus and bilateral optic atrophy (7) . Insulin-dependent diabetes usually occurs as the initial manifestation during the first decade of life, whereas the diagnosis of Wolfram syndrome is invariably later, with onset of symptoms in the second and ensuing decades (7, 10, 11) . Two causative genes for this genetic disorder have been identified and named Wolfram syndrome 1 (WFS1) and Wolfram syndrome 2 (WFS2) (12, 13) . It has been shown that multiple mutations in the WFS1 gene, as well as a specific mutation in the WFS2 gene, lead to β cell death and neurodegeneration through ER and mitochondrial dysfunction (5, 6, 14-16). WFS1 gene variants are also associated with a risk of type 2 diabetes (17) . Moreover, a specific WFS1 variant can cause autosomal dominant diabetes (18) , raising the possibility that this rare disorder is relevant to common molecular mechanisms altered in diabetes and other human chronic diseases in which ER dysfunction is involved.
Despite the underlying importance of ER malfunction in Wolfram syndrome, and the identification of WFS1 and WFS2 genes, a molecular mechanism linking the ER to death of neurons and β cells has not been elucidated. Here we show that the calpain protease provides a mechanistic link between the ER and death of neurons and β cells in Wolfram syndrome.
Results
The causative genes for Wolfram syndrome, WFS1 and WFS2, encode transmembrane proteins localized to the ER (5, 12, 13) . Mutations in the WFS1 or WFS2 have been shown to induce neuronal and β cell death. To determine the cell death pathways emanating from the ER, we sought proteins associated with Wolfram syndrome causative gene products. HEK293 cells were transfected with a GST-tagged WFS2 expression plasmid. The GST-WFS2 protein was purified along with associated proteins on a glutathione affinity resin. These proteins were separated by
Significance
Wolfram syndrome is an autosomal recessive disorder characterized by juvenile diabetes and neurodegeneration, and is considered a prototype of human endoplasmic reticulum (ER) disease. Wolfram syndrome is caused by loss of function mutations of Wolfram syndrome 1 or Wolfram syndrome 2 genes, which encode transmembrane proteins localized to the ER. Despite its rarity, Wolfram syndrome represents the best human disease model currently available to identify drugs and biomarkers associated with ER health. Furthermore, this syndrome is ideal for studying the mechanisms of ER stress-mediated death of neurons and β cells. Here we report that the pathway leading to calpain activation offers potential drug targets for Wolfram syndrome and substrates for calpain might serve as biomarkers for this syndrome.
SDS/PAGE and visualized by Coomassie staining. Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectroscopic analysis revealed 13 interacting proteins (Table S1) , and one of the WFS2-associated polypeptides was CAPN2, the catalytic subunit of calpain 2, a member of the calcium dependent cysteine proteases family whose members mediate diverse biological functions including cell death (19) (20) (21) (Fig. 1A) . Previous studies have shown that calpain 2 activation is regulated on the ER membrane and it plays a role in ER stress-induced apoptosis and β cell death (20, (22) (23) (24) , which prompted us to study the role of WFS2 in calpain 2 activation.
Calpain 2 is a heterodimer consisting the CAPN2 catalytic subunit and the CAPNS1 (previously known as CAPN4) regulatory subunit. We first verified that WFS2 interacts with calpain 2 by showing that endogenous calpain 2 subunits CAPN2 (Fig. 1B) and CAPNS1 (Fig. 1C) each associated with GST-tagged WFS2 expressed in HEK293 cells. Endogenous CAPN2 was also found to be coimmunoprecipated with N-or C-terminal FLAG-tagged WFS2 expressed in HEK293 cells (Fig. S1 A and B, respectively) . To further confirm these findings, we performed a coimmunoprecipitation experiment in Neuro2a cells (a mouse neuroblastoma cell line) and INS-1 832/13 cells (a rat pancreatic β cell line) and found that endogenous WFS2 interacted with endogenous CAPN2 (Fig. 1 D and E) . WFS2 is known to be a transmembrane protein localized to the ER. We therefore explored the possibility that calpain 2 might also localize to the ER. We transfected COS7 cells with pDsRed2-ER vector to visualize ER. Immunofluorescence staining of COS7 cells showed that endogenous calpain 2 was mainly localized to the cytosol, but also showed that a small portion colocalized with DsRed2-ER protein at the ER (Fig. 1F ). Cell fractionation followed by immunoblot further confirmed this observation (Fig. S1C) . Collectively, these results suggest that calpain 2 interacts with WFS2 at the cytosolic face of the ER. Calpain hyperactivation has been shown to contribute to cell loss in various diseases (19) , raising the possibility that calpain 2 might be involved in the regulation of cell death. To verify this issue, we overexpressed CAPN2, the catalytic subunit of calpain 2, and observed increase of cleaved caspase-3 in HEK293 cells indicating that hyperactivation of calpain 2 induces cell death (Fig. 1G) .
To determine whether WFS2 plays a role in cell survival, we suppressed WFS2 expression in mouse neuronal NSC34 cells using siRNA and measured cell death under normal and ER stress conditions. WFS2 knockdown was associated with increased cleavage of caspase-3 in normal or ER stressed conditions ( Fig. 2 A  and B) . We subsequently evaluated calpain 2 activation by measuring the cleavage of alpha II spectrin, a substrate for calpain 2. RNAi-mediated knockdown of WFS2 induced calpain activation, especially under ER stress conditions ( Fig. 2A) .
In patients with Wolfram syndrome, destruction of β cells leads to juvenile-onset diabetes (25) . This finding prompted us to examine whether WFS2 was also involved in pancreatic β cell death. As was seen in neuronal cells, knockdown of WFS2 in rodent β cell lines INS1 832/13 ( Fig. 2C ) and MIN6 (Fig. S2 ) was also associated with increased caspase-3 cleavage under both normal and ER stress conditions. The association of WFS2 with calpain 2 and their involvement in cell viability suggested that calpain 2 activation might be the cause of cell death in WFS2-deficient cells. To further explore the relationship between WFS2 and calpain 2, we expressed WFS2 together with the calpain 2 catalytic subunit CAPN2 and measured apoptosis. Ectopic expression of WFS2 significantly suppressed calpain 2-associated apoptosis under normal and ER stress conditions (Fig. 2D , lane 4 and lane 8, and Fig. 2E ). Next, we tested whether CAPN2 mediates cell death induced by WFS2 deficiency. When CAPN2 was silenced in WFS2-deficient cells, apoptosis was partially suppressed compared with untreated WFS2-deficient cells (Fig. 2F) . Taken together, these results suggest that WFS2 is a negative regulator of calpain 2 proapoptotic functions.
To further confirm that loss of function of WFS2 leads to cell death mediated by calpain 2, we tested if calpeptin, a calpain inhibitor, could prevent cell death in WFS2-deficient cells. In agreement with previous observations, calpeptin treatment prevented WFS2-knockdown-mediated cell death in neuronal ( Fig. 3 A and B) and β cell lines (Fig. 3C and Fig. S3A ). Collectively, these results indicate that WFS2 is a suppressor of calpain 2-mediated cell death.
CAPN2 is the catalytic subunit of calpain 2. CAPN2 forms a heterodimer with the regulatory subunit, CAPNS1, which is required for protease activity and stability. We next explored the role of WFS2 in CAPN2 and CAPNS1 protein stability. Ectopic expression or RNAi-mediated knockdown of WFS2 did not correlate with changes in the steady-state expression of CAPN2 (Fig. S3B) . By contrast, overexpression of WFS2 significantly reduced CAPNS1 protein expression (Fig. 3D ) and transient suppression of WFS2 slightly increased CAPNS1 protein expression (Fig. 3D ). These data suggest that WFS2 might be involved in CAPNS1 protein turnover, which is supported by the data showing that GST-tagged WFS2 expressed in HEK293 cells associated with endogenous CAPNS1 (Fig. 1C) . To investigate whether WFS2 regulates CAPNS1 stability through the ubiquitin-proteasome pathway, we treated HEK293 cells ectopically expressing WFS2 with a proteasome inhibitor, MG132, and then measured CAPNS1 protein level. MG132 treatment stabilized CAPNS1 protein in cells ectopically expressing WFS2 (Fig. 3E) . Furthermore, we performed cycloheximide chase experiments using HEK293 cells ectopically expressing WFS2 and quantified CAPNS1 protein levels at different time points. Ectopic expression of WFS2 was associated with significantly accelerated CAPNS1 protein loss, indicating that WFS2 contributes to posttranslational regulation of CAPNS1 (Fig. 3F) . To further assess whether WFS2 is involved in the ubiquitination of CAPNS1, we measured the levels of CAPNS1 ubiquitination in cells ectopically expressing WFS2 and observed that CAPNS1 ubiquitination was increased by ectopic expression of WFS2 (Fig. 3G) .
To further investigate the role of WFS2 in calpain 2 regulation, we collected brain lysates from WFS2 knockout mice. Measured levels of cleaved spectrin, a well characterized substrate for calpain (26) . Notably, protein expression levels of cleaved spectrin, as well as CAPNS1, were significantly increased in WFS2 knockout mice compared with control mice (Fig. 3H) . Collectively, these results indicate that WFS2 inhibits calpain 2 activation by regulating CAPNS1 degradation mediated by the ubiquitinproteasome system.
Calpain 2 is a calcium-dependent protease. WFS1, the other causative gene for Wolfram syndrome, has been shown to be involved in calcium homeostasis (27, 28) , suggesting that the loss of function of WFS1 may also cause calpain activation. To evaluate this possibility, we measured calpain activation levels in brain tissues from WFS1 brain-specific knockout and control mice. We observed a significant increase in a calpain-specific spectrin cleavage product, reflecting higher calpain activation levels in WFS1 knockout mice compared with control mice (Fig.  4A ). The suppression levels of WFS1 in different parts of the brain were shown in Fig. 4B . To further confirm that calpain is activated by the loss of WFS1, we looked for other calpain substrates in brain tissues from WFS1 knockout mice using a proteomics approach. Two-dimensional fluorescence gel electrophoresis identified 12 proteins differentially expressed between cerebellums of WFS1 knockout mice and those of control mice ( Fig. 4 C and D) . Among these, myelin basic protein (MBP) is a known substrate for calpain in the brain (29) . We measured myelin basic protein levels in brain lysates from WFS1 knockout and control mice. Indeed, the cleavage and degradation of myelin basic protein was increased in WFS1 knockout mice relative to control mice (Fig. 4E) .
Next, we looked for evidence of increased calpain activity in Wolfram syndrome patient cells. We created neural progenitor cells derived from induced pluripotent stem cells (iPSCs) of Wolfram syndrome patients with mutations in WFS1. Fibroblasts from four unaffected controls and five patients with Wolfram syndrome were transduced with four reprogramming genes (Sox2, Oct4, c-Myc, and Klf4) (30) (Table S2) . We produced at least 10 iPSC clones from each control and Wolfram patient. All control-and Wolfram-iPSCs, exhibited characteristic human embryonic stem cell morphology, expressed pluripotency markers including ALP, NANOG, SOX2, SSEA4, TRA-1-81, and had a normal karyotype ( Fig. 5 A-F) . To create neural progenitor cells, we first formed neural aggregates from iPSCs. Neural aggregates were harvested at day 5, replated onto new plates to give rise to colonies containing neural rosette structures. At day 12, neural rosette clusters were collected, replated, and used as neural progenitor cells. Consistent with the data from WFS1 and WFS2 knockout mice, we observed that spectrin cleavage was increased in neural progenitor cells derived from Wolfram-iPSCs relative to control iPSCs, which indicates increased calpain activity (Fig. 5G) .
Because calpain is known to be activated by high calcium, we explored the possibility that cytoplasmic calcium may be increased in patient cells by staining neural progenitor cells derived from control-and Wolfram-iPSCs with Fura-2, a fluorescent calcium indicator which enables accurate measurements of cytoplasmic calcium concentrations. Fig. 5H , Left, shows that cytoplasmic calcium levels were higher in Wolfram-iPSC-derived neuronal cells relative to control cells. This result was confirmed by staining these cells with another fluorescent calcium indicator, Fluo-4 ( Fig. 5H , Right). Collectively, these results indicate that loss of function of WFS1 increases cytoplasmic calcium levels, leading to calpain activation.
The results shown above argue that the pathway leading to calpain activation provides potential therapeutic targets for Wolfram syndrome. To test this concept, we elected to focus on modulating cytosolic calcium and performed a small-scale screen to identify chemical compounds that could prevent cell death mediated by thapsigargin, a known inhibitor for ER calcium ATPase. Among 73 well characterized chemical compounds that we tested (Table S3 ), 8 could significantly suppress thapsigarginmediated cell death. These were PARP inhibitor, dantrolene, NS398, pioglitazone, calpain inhibitor III, docosahexaenoic acid (DHA), rapamycin, and GLP-1 (Fig. 6A) . GLP-1, pioglitazone, and rapamycin are FDA-approved drugs and have been shown to confer protection against ER stress-mediated cell death (27, (31) (32) (33) . Dantrolene is another FDA-approved drug clinically used for muscle spasticity and malignant hyperthermia (34) . Previous studies have shown that dantrolene is an inhibitor of the ER-localized ryanodine receptors and suppresses leakage of calcium from the ER to cytosol (35, 36) . We thus hypothesized that dantrolene could confer protection against cell death in Wolfram syndrome, and performed a series of experiments to investigate this possibility. We first examined whether dantrolene could decrease cytoplasmic calcium levels. As expected, dantrolene treatment decreased cytosolic calcium levels in INS-1 832/13 and NSC34 cells (Fig. S4 A and B) . We next asked whether dantrolene could restore cytosolic calcium levels in WFS1-deficient cells. RNAimediated WFS1 knockdown increased cytosolic calcium levels relative to control cells, and dantrolene treatment restored cytosolic calcium levels in WFS1-knockdown INS-1 832/13 cells (Fig.  6B , Left) as well as WFS1-knockdown NSC34 cells (Fig. 6B, Right) . Next, to determine whether dantrolene confered protection in WFS1-deficient cells, we treated WFS1 silenced INS-1 832/13 cells with dantrolene and observed suppression of apoptosis (Fig. 6C ) and calpain activity (Fig. 6D) . Dantrolene treatment also prevented (G) NSC34 cells were transfected with mock empty vector, FLAG tagged ubiquitin (Ub-FLAG) plasmid or cotransfected with WFS2 expression plasmid and Ub-FLAG plasmid. Cell lysates were immunoprecipitated with FLAG affinity beads and analyzed for ubiquitin conjugated proteins by immunoblotting. Levels of CAPNS1 and Ub-FLAG protein were measured in the precipitates. WFS2, CAPNS1 and actin expression was monitored in the input samples. (H) Brain lysates from control and WFS2 knockout mice were analyzed by immunoblotting. Protein levels of cleaved spectrin and CAPNS1 were determined (Left) and quantified (Center and Right) (each group n = 3, *P < 0.05).
calpain activation and cell death in WFS1-knockdown NSC34 cells (Fig. 6E) . To verify these observations in patient cells, we pretreated neural progenitor cells derived from iPSCs of a Wolfram syndrome patient and an unaffected parent with dantrolene, and then challenged these cells with thapisgargin. Thapsigargin-induced cell death was increased in neural progenitor cells derived from the Wolfram syndrome patient relative to those derived from the unaffected parent, and dantrolene could prevent cell death in the patient iPSC-derived neural progenitor cells (Fig. 6F ). In addition, we treated brain-specific WFS1 knockout mice with dantrolene and observed evidence of suppressed calpain activation in brain lysates from these mice (Fig. 6G) . Collectively, these results argue The protein expression ratios between WFS1 knockout and control mice were generated, and differentially expressed spots were analyzed by MALDI-TOF mass spectrometry. Quantitative diagrams of spots #2 and #3, identified by mass spectrometry as myelin basic protein, showing lower levels of expression in WFS1 knockout mice compared with control mice. (E) Protein was extracted from cerebellums of WFS1 brain-specific knockout (−/−) and control (+/+) mice. Cleaved myelin basic protein (black arrow), cleaved spectrin, WFS1 and GAPDH levels were determined by immunoblot analysis (left panel) and quantified in the right panel (each group n = 3, *P < 0.05).
that dantrolene could prevent cell death in Wolfram syndrome by suppressing calpain activation.
Discussion
Growing evidence indicates that ER dysfunction triggers a range of human chronic diseases, including diabetes, atherosclerosis, inflammatory bowel disease, and neurodegenerative diseases (3, 4, 37-39). However, currently there is no effective therapy targeting the ER for such diseases due to the lack of clear understanding of the ER's contribution to the pathogenesis of these diseases. Although Wolfram syndrome is a rare disease and therefore not a focus of drug discovery efforts, the homogeneity of the patient population and disease mechanism has enabled us to identify a potential target, a calcium-dependent protease, calpain. Our results provide new insights into how the pathways leading to calpain activation cause β cell death and neurodegeneration, which are schematically summarized in Fig. 6H .
There are two causative genes for Wolfram syndrome, WFS1 and WFS2. The functions of WFS1 have been extensively studied in pancreatic β cells. It has been shown that WFS1-deficient pancreatic β cells have high baseline ER stress levels and impaired insulin synthesis and secretion. Thus, WFS1-deficient β cells are susceptible to ER stress mediated cell death (5, 6, 32, (40) (41) (42) . The functions of WFS2 are still not clear. There is evidence showing that impairment of WFS2 function can cause neural atrophy, muscular atrophy, and accelerate aging in mice (14) . WFS2 has also been shown to be involved in autophagy (43) . However, although patients with both genetic types of Wolfram syndrome suffer from the same disease manifestations, it was not clear if a common molecular pathway was altered in these patients. Our study has demonstrated, to our knowledge for the first time, that calpain hyperactivation is the common molecular pathway altered in patients with Wolfram syndrome. The mechanisms of calpain hyperactivation are different in the two genetic types of Wolfram syndrome. WFS1 mutations cause calpain activation by increasing cytosolic calcium levels, whereas WFS2 mutations lead to calpain activation due to impaired calpain inhibition.
Previously, Wolfram syndrome studies focused on pancreatic β cell function (5, 40, 41) . However, patients also suffer from neuronal manifestations. MRI scans of Wolfram syndrome patients showed atrophy in brain tissue implying neurodegeneration in patients (7, 10) . To investigate the mechanisms of neurodegeneration in Wolfram syndrome human cells, we established Wolfram syndrome iPSC-derived neural progenitor lines and confirmed the observations found in rodent cells and animal models of Wolfram syndrome. Differentiation of these iPSCderived neural progenitor cells into specific types of neurons should be carried out in the future to better understand which cell types are damaged in Wolfram syndrome; this will lead to a better understanding of the molecular basis of this disease and provide cell models for future drug development.
Calpain activation has been found to be associated with type 2 diabetes and various neuronal diseases including Alzheimers, traumatic brain injury and cerebral ischemia, suggesting that regulation of calpains is crucial for cellular health (23) . We discovered that calpain inhibitor III could confer protection against thapsigargin mediated cell death (Fig. 6A) . Our data also demonstrates that calpeptin treatment was beneficial for cells with impaired WFS2 function. These results suggest that targeting calpain could be a novel therapeutic strategy for Wolfram syndrome. However, calpain is also an essential molecule for cell survival (44) . Controlling calpain activation level is a doublebladed sword. We should carefully monitor calpain functions in treating patients with Wolfram syndrome (44).
Calpain activation is tightly regulated by cytosolic calcium levels. In other syndromes that increase cytosolic calcium level in pancreatic β cells, patients experience a transient or permanent period of hyperinsulinaemic hypoglycemia. This hyperinsulinaemic hypoglycemia can be partially restored by an inhibitor for ATPsensitive potassium (K ATP ) channels or a calcium channel antagonist that prevents an increase in cytosolic calcium levels (45, 46 reduces calcium leakage from the ER to cytosol, lowering cytosolic calcium level. The protective effect of dantrolene treatment on WFS1-deficient cells suggests that dysregulated cellular calcium homeostasis plays a role in the disease progression of Wolfram syndrome. In addition, it has been shown that stabilizing ER calcium channel function could prevent the progression of neurodegeneration in a mouse model of Alzheimer's disease (48) . Therefore, modulating calcium levels may be an effective way to treat Wolfram syndrome or other ER diseases.
Dantrolene treatment did not block cell death mediated by WFS2 knockdown, suggesting that WFS2 does not directly affect the ER calcium homeostasis (Fig. S4 D and E) . RNAi-mediated WFS1 knockdown in HEK293 cells significantly reduced the activation levels of sarco/endoplasmic reticulum calcium transport ATPase (SERCA), indicating that WFS1 may play a role in the modulation of SERCA activation and ER calcium levels (Fig.  S5) . It has been shown that WFS1 interacts with the Na + /K + ATPase β1 subunit and the expression of WFS1 parallels that of Na + /K + ATPase β1 subunit in a variety of settings, suggesting that WFS1 may function as an ion channel or regulator of existing channels (42) . Further studies on this topic would be necessary to completely understand the etiology of Wolfram syndrome.
Our study reveals that dantrolene can prevent ER stressmediated cell death in human and rodent cell models as well as mouse models of Wolfram syndrome. Thus, dantrolene and other drugs that regulate ER calcium homeostasis could be used to delay the progression of Wolfram syndrome and other diseases associated with ER dysfunction, including type 1 and type 2 diabetes. Animal Experiments. WFS1 brain-specific knockout mice were generated by breeding the Nestin-Cre transgenic mice (Jackson Laboratory) with WFS1 floxed mice (40) . WFS2 whole body knockout mice are purchased from MRC Harwell. All animal experiments were performed according to procedures approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (A-3381-01).
Calcium Levels. Calcium levels in cells were measured by Fura-2 AM dye and Fluo-4 AM dye (Life Technology) Inifinite M1000 (Tecan). Cells were plated in 96-well plates at 25,000 cells per well and stained with 4 μg/mL Fura-2 dye along with 2.5 mM probenecid for 30 min, then the cells were washed with PBS and kept in the dark for another 30 min to allow cleavage of AM ester. Fluorescence was measured at excitation wavelength 510 nm and emission wavelengths 340 nm and 380 nm. Then background subtractions were performed with both emission wavelengths. The subtraction result was used to calculate 340/380 ratios.
For Fluo-4 AM staining, neural progenitor cells were plated in 24-well plates at 200,000 cells per well. After staining with Fluo-4 AM dye for 30 min along with 2.5 mM probenecid, cells were washed and resuspended in PBS. Incubation for a further 30 min was performed to allow complete deesterification of intracellular AM esters. Then, samples were measured by flow cytometry at the FACS core facility of Washington University School of Medicine using a LSRII instrument (BD). The results were analyzed by FlowJo ver.7.6.3.
Statistical Analysis. Two-tailed t tests were used to compare the two treatments. P values below 0.05 were considered significant. All values are shown as means ± SD if not stated. Please see SI Materials and Methods for complete details.
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Reagents. Thapsigargin, tunicamycin, calpeptin dantrolene, ryanodine, and cycloheximide were obtained from SIGMA. RPMI-1640 and DMEM were from Invitrogen. Neural induction media, neural proliferation media were from Stemcell Technologies. MitoProbe DilC1(5) mitochondrial membrane potential assay kit, Annexin V Alexa Flour488 conjugate, Fluo-4, and Fura-2 calcium indicators were obtained from Invitrogen. Caspase-glo 3/7 protease assay kit and calpain-glo protease assay kit was purchased from Promega. Mito Stress test kit was from Seahorse Bioscience. Anti-WFS2 antibody, and anti-WFS1 antibody were purchased from Proteintech, anti-Caspase 3, anti-CAPN2 antibodies were obtained from Cell Signaling Technology, anti-CAPNS1 and antialpha II spectrin antibody were obtained from Millipore. Antiactin antibody was purchased from SIGMA. Anti-Myelin basic protein antibody was from Santa Cruz Biotechnology. AntiCalpain 2 antibody, which detects both CAPN2 and CAPNS1, was raised in rabbits against bacterially expressed rat calpain 2.
Plasmids and siRNA. pCMV-SPORT6-WFS2 expression plasmid was purchased from Open Biosystems. pDsRed2-ER vector was purchased from Clontech. FLAG-tagged WFS2 plasmids were constructed by inserting FLAG sequences into the N and C termini of the expression plasmid. GST-WFS2 plasmid was generated by inserting WFS2 sequence into pEBG mammalian expression plasmid. A CAPN2 expression plasmid was generated in pLenti-CMVpuro plasmid provided by E. Campeau (1). Lipofectamine2000 (Invitrogen) was used to transfect small interfering RNA (siRNA) directed against WFS2 and CAPN2 into cells. siRNAs were designed and synthesized at QIAGEN as follows: mouse WFS2 CA-ACAGAAGGAUAGCUUG, human WFS2 CGAAAGUAGU-GAAUGAAA, human CAPN2 CCGAGGAGGUUGAAAGUA, rat WFS1 GUUUGACCGCUACAAGUUU. Cells were incubated in media overnight after siRNA transfection, and then additional treatments were performed, including ER stress induction.
Cell Culture. Neuro-2a, NSC34, HEK293, MEFs, and COS7 cells were cultured in DMEM containing 10% (vol/vol) FBS and penicillin and streptomycin. MIN6 cells were grown in DMEM containing 15% FBS and penicillin and streptomycin. INS-1 832/13 cells were cultured in RPMI containing 10% FBS before measurement. Neural progenitor cells were maintained in STEMdiff Neural Progenitor Medium from Stemcell Technologies.
iPS Cell and Neural Progenitor Cell Generation. To generate iPS cells, we obtained fibroblasts from nonaffected controls and patients with Wolfram syndrome. Integration-free iPS cells were generated via Sendai viral delivery of the four reprogramming factors, Oct4, Sox2, Klf4, and c-Myc using Life Technologies' Cytotune reagents and protocol. All WFS-and control-iPSCs showed silencing of the four transgenes, exhibited characteristic human embryonic stem cell morphology, expressed pluripotency markers including ALP, NANOG, SOX2, SSEA4, and TRA-1-81, and had a normal karyotype. To generate neural progenitor cells, iPSCs were counted and plated ∼50,000 per well in a 96-well plate to form uniform embryoid bodies. After 5 d, embryoid bodies were suspended in neural induction media and replated as adherent cultures. Fresh media were applied every day for 7 d. Neural rosettes formed in these cultures were selected and plated. Plated rosettes were fed with neural induction media every day for 4-7 d to obtain neural progenitor cells.
MALDI-TOF Mass Spectrometry. HEK293 cells were transfected with GST-WFS2 plasmid and empty GST plasmid. Cell lysates were collected and immunoprecipitated with glutathione beads in lysis buffer (150 mM NaCl, 0.5% Triton X-100, 50 mM Hepes, 1 mM EDTA, 1 mM DTT, pH 7.5). The precipitated proteins from both samples were resolved by SDS/PAGE and stained with Coomassie blue staining. The distinct bands that only appear in GST-WFS2 lane but not GST lane were analyzed by MALDI-TOF tandem mass spectrometry on a Shimadzu Axima TOF2 mass spectrometry at University of Massachusetts Medical School Proteomics and mass spectrometry facility.
Immunostaining. Cells were fixed in 4% paraformaldehyde for 30 min at room temperature and then permeabilized with 0.1% Triton X-100 for 2 min. The fixed cells were washed with PBS/ Tween 0.1%, blocked with Image-It FX signal enhancer (Invitrogen) for 1 h, and incubated in primary antibody overnight at 4°C. The cells were washed three times in PBS/Tween 0.1% and incubated with secondary antibody for 1 h at room temperature. Images were obtained with a Zeiss LSM 5 PASCAL confocal microscope with LSM Image software. Quantitative Real-Time PCR. Total RNA was extracted by RNeasy kits (Qiagen). Reverse transcriptase PCR was performed using High capacity reverse transcription kit (Applied Biosystems) and quantitative PCR was demonstrated with Applied Biosystems ViiA7 using SYBR green dye.
2D Fluorescence Difference Gel Electrophoresis. Proteins were extracted from cerebellums from WFS1 knockout mice and control mice. Equal amount of protein extract from paired samples were labeled by CyDye DIGE fluors. The spectrally resolvable dyes enabled simultaneous coseparation and analysis of samples on a single multiplexed gel. These paired samples were simultaneously separated on a single 2D gel, using isoelectric focusing (IEF) in the first dimension and SDS polyacrylamide gel electrophoresis (SDS/PAGE) in the second dimension. After electrophoresis, the gel was scanned using a Typhoon image scanner. Each scan revealed one of the CyDye signals (Cy3 and Cy5). ImageQuant software was used to generate the image presentation data including the single and overlay images. The comparative analysis of all spots was done by the DeCyder analysis software. The protein expression ratios between WFS1 knockout and control mice were generated, and differentially expressed spots were analyzed by MALDI-TOF mass spectrometry.
SERCA Activity Assay. The SERCA activity assay was performed as described in ref. 2 . HEK293 cells were homogenized in hypotonic buffer, consisting of 10 mM NaHCO 3 , 250 mM sucrose, 5 mM NaN 3 , and 0.1 mM PMSF. ER fractions were isolated using differential centrifugation. 125-300 μg of ER protein fractions were added to the assay mixture [100 mM KCL, 30 mM imidazolehistidine (pH 6.8), 5 mM MgCl 2 , 5 mM ATP, 5 mM (COOK) 2 3 . The mix was then vacuum filtered through a 0.2-μm HT Tuffryn membrane (Sigma). SERCA-dependent calcium transport was measured by comparing calcium transport in the presence or absence of 10 μM thapsigargin, a SERCA inhibitor. n.s. Fig. S4 . INS-1 832/13 (A) and NSC34 (B) cells were pretreated with or without 10 μM dantrolene for 24 h. Cytoplasmic calcium levels were measured by Fura-2 calcium indicator over a period. Thapsigargin was added at 0 min time point (n = 6, the experiment was repeated six independent times). (C) INS-1 832/13 cells were transfected with scrambled siRNA (Cont) or WFS1 siRNA. Twenty-four h after transfection, cells were treated with or without 2 μM ryanodine for 24 h. Cleaved caspase 3, WFS1, and GAPDH levels were monitored by immunoblotting (Left) and quantified (Right) (n = 3, *P < 0.05). (D and E) INS-1 832/13 cells (D) and NSC34 cells (E) were transfected with scrambled siRNA (Cont) and WFS2 siRNA. Twenty-four h after transfection, cells were treated with or without 10 μM dantrolene for 24 h. Cleaved caspase 3, WFS2 and GAPDH levels were monitored by immunoblotting. Quantification of cleaved caspase 3 protein levels are shown to the right (n = 3, *P < 0.05). (Control) . All values are means ± SEM. For the wild-type condition, n = 6; the experiment was repeated six independent times. For the WFS1 knockdown condition, n = 7; the experiment was repeated seven independent times. *P < 0.05. (B) Protein levels of WFS1 and actin were monitored in HEK293 cells stably expressing shRNA directed against WFS1 or a scrambled shRNA (Control). Quantification is shown on the right (n = 3, *P < 0.05). 
